
Legend Biotech Reports First Quarter 2025 Results And Recent Highlights
(MENAFN- GlobeNewsWire - Nasdaq) CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 million Over 6,000 patients treated to date Initiated CARVYKTI® clinical production at the Tech Lane facility Received positive CHMP …